Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.

Saved in:
Bibliographic Details
Title: Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
Authors: Lucas DM; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA., Ruppert AS; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA., Lozanski G; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA., Dewald GW; b Mayo Clinic , Rochester , MN , USA., Lozanski A; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA., Claus R; c University of Freiburg Medical Center , Freiburg , Germany.; d German Cancer Research Center , Heidelberg , Germany., Plass C; d German Cancer Research Center , Heidelberg , Germany., Flinn IW; e Sarah Cannon Research Institute and Tennessee Oncology , Nashville , TN , USA., Neuberg DS; f Dana Farber Cancer Institute , Boston , MA , USA., Paietta EM; g Montefiore Medical Center , Bronx , NY , USA., Bennett JM; h University of Rochester , Rochester , NY , USA., Jelinek DF; b Mayo Clinic , Rochester , MN , USA., Gribben JG; i Barts Cancer Institute, Queen Mary University of London , London , UK., Hussein MA; j Celgene Corporation , Summit , NJ , USA., Appelbaum FR; k Fred Hutchinson Cancer Research Center , Seattle , WA , USA., Larson RA; l University of Chicago , Chicago , IL , USA., Moore DF Jr; m Cancer Center of Kansas , Wichita , KS , USA., Tallman MS; n Memorial Sloan Kettering Cancer Center , New York , NY , USA., Byrd JC; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA., Grever MR; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2015; Vol. 56 (11), pp. 3031-7. Date of Electronic Publication: 2015 Mar 30.
Publication Type: Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 25721902
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lucas+DM%22">Lucas DM</searchLink>; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA.<br /><searchLink fieldCode="AU" term="%22Ruppert+AS%22">Ruppert AS</searchLink>; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA.<br /><searchLink fieldCode="AU" term="%22Lozanski+G%22">Lozanski G</searchLink>; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA.<br /><searchLink fieldCode="AU" term="%22Dewald+GW%22">Dewald GW</searchLink>; b Mayo Clinic , Rochester , MN , USA.<br /><searchLink fieldCode="AU" term="%22Lozanski+A%22">Lozanski A</searchLink>; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA.<br /><searchLink fieldCode="AU" term="%22Claus+R%22">Claus R</searchLink>; c University of Freiburg Medical Center , Freiburg , Germany.; d German Cancer Research Center , Heidelberg , Germany.<br /><searchLink fieldCode="AU" term="%22Plass+C%22">Plass C</searchLink>; d German Cancer Research Center , Heidelberg , Germany.<br /><searchLink fieldCode="AU" term="%22Flinn+IW%22">Flinn IW</searchLink>; e Sarah Cannon Research Institute and Tennessee Oncology , Nashville , TN , USA.<br /><searchLink fieldCode="AU" term="%22Neuberg+DS%22">Neuberg DS</searchLink>; f Dana Farber Cancer Institute , Boston , MA , USA.<br /><searchLink fieldCode="AU" term="%22Paietta+EM%22">Paietta EM</searchLink>; g Montefiore Medical Center , Bronx , NY , USA.<br /><searchLink fieldCode="AU" term="%22Bennett+JM%22">Bennett JM</searchLink>; h University of Rochester , Rochester , NY , USA.<br /><searchLink fieldCode="AU" term="%22Jelinek+DF%22">Jelinek DF</searchLink>; b Mayo Clinic , Rochester , MN , USA.<br /><searchLink fieldCode="AU" term="%22Gribben+JG%22">Gribben JG</searchLink>; i Barts Cancer Institute, Queen Mary University of London , London , UK.<br /><searchLink fieldCode="AU" term="%22Hussein+MA%22">Hussein MA</searchLink>; j Celgene Corporation , Summit , NJ , USA.<br /><searchLink fieldCode="AU" term="%22Appelbaum+FR%22">Appelbaum FR</searchLink>; k Fred Hutchinson Cancer Research Center , Seattle , WA , USA.<br /><searchLink fieldCode="AU" term="%22Larson+RA%22">Larson RA</searchLink>; l University of Chicago , Chicago , IL , USA.<br /><searchLink fieldCode="AU" term="%22Moore+DF+Jr%22">Moore DF Jr</searchLink>; m Cancer Center of Kansas , Wichita , KS , USA.<br /><searchLink fieldCode="AU" term="%22Tallman+MS%22">Tallman MS</searchLink>; n Memorial Sloan Kettering Cancer Center , New York , NY , USA.<br /><searchLink fieldCode="AU" term="%22Byrd+JC%22">Byrd JC</searchLink>; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA.<br /><searchLink fieldCode="AU" term="%22Grever+MR%22">Grever MR</searchLink>; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007422%22">Leukemia & lymphoma</searchLink> [Leuk Lymphoma] 2015; Vol. 56 (11), pp. 3031-7. <i>Date of Electronic Publication: </i>2015 Mar 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9007422 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1029-2403 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210268022%22">10268022 </searchLink><i>NLM ISO Abbreviation: </i>Leuk Lymphoma <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=25721902
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3109/10428194.2015.1023800
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3031
    Titles:
      – TitleFull: Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lucas DM
      – PersonEntity:
          Name:
            NameFull: Ruppert AS
      – PersonEntity:
          Name:
            NameFull: Lozanski G
      – PersonEntity:
          Name:
            NameFull: Dewald GW
      – PersonEntity:
          Name:
            NameFull: Lozanski A
      – PersonEntity:
          Name:
            NameFull: Claus R
      – PersonEntity:
          Name:
            NameFull: Plass C
      – PersonEntity:
          Name:
            NameFull: Flinn IW
      – PersonEntity:
          Name:
            NameFull: Neuberg DS
      – PersonEntity:
          Name:
            NameFull: Paietta EM
      – PersonEntity:
          Name:
            NameFull: Bennett JM
      – PersonEntity:
          Name:
            NameFull: Jelinek DF
      – PersonEntity:
          Name:
            NameFull: Gribben JG
      – PersonEntity:
          Name:
            NameFull: Hussein MA
      – PersonEntity:
          Name:
            NameFull: Appelbaum FR
      – PersonEntity:
          Name:
            NameFull: Larson RA
      – PersonEntity:
          Name:
            NameFull: Moore DF Jr
      – PersonEntity:
          Name:
            NameFull: Tallman MS
      – PersonEntity:
          Name:
            NameFull: Byrd JC
      – PersonEntity:
          Name:
            NameFull: Grever MR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2015
              Type: published
              Y: 2015
          Identifiers:
            – Type: issn-electronic
              Value: 1029-2403
          Numbering:
            – Type: volume
              Value: 56
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Leukemia & lymphoma
              Type: main
ResultId 1